Evidence map›Paper›PMID 23453090›Full record

Trial reportAmerican heart journal2013

INtensive versus standard ambulatory blood pressure lowering to prevent functional DeclINe in the ElderlY (INFINITY).

William B White, Ravi Marfatia, Julia Schmidt, Dorothy B Wakefield, Richard F Kaplan, Richard W Bohannon, Charles B Hall, Charles R Guttmann, Nicola Moscufo, Douglas Fellows and 1 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American heart journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 7 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 7 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Blood pressure targets for hypertension in older adults.The Cochrane database of systematic reviews · 2017
    Pooled it
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Observational
  17. Review
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

William B WhiteUniversity of Connecticut School of Medicine, Farmington, CT, USA. wwhite@nso1.uchc.edu
Ravi Marfatia
Julia Schmidt
Dorothy B Wakefield
Richard F Kaplan
Richard W Bohannon
Charles B Hall
Charles R Guttmann
Nicola Moscufo
Douglas Fellows
Leslie Wolfson
University of Connecticut · USAlbert Einstein College of Medicine · USBrigham and Women's Hospital · USHarvard University · US

Funding

ZONISAMIDE VERSUS PLACEBOM01RR006192 · NCRR · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI CLOUTIER, MICHELLE M. · 1994 to 2008
$22.1M
Intensive Blood Pressure Reduction to Lessen Functional DeclineR01AG022092 · NIA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI WHITE, WILLIAM BARRY, WOLFSON, LESLIE · 2004 to 2017
$6.6M
Contingency Management for Initiating Smoking AbstinenceR01DA024667 · NIDA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI WHITE, WILLIAM BARRY · 2008 to 2012
$2.8M
NCRR NIH HHS M01 RR006192NIA NIH HHS R01 AG022092NIA NIH HHS R01AG022092NIDA NIH HHS R01 DA024667
6 · The paper itself

Abstract

Reductions in mobility and cognitive function linked to accrual of brain microvascular disease related white matter hyperintensities (WMHs) on magnetic resonance imaging can occur in older hypertensive patients in as little as 2 years. We have designed a trial evaluating 2 levels of ambulatory blood pressure (ABP) control in individuals with normal or mildly impaired mobility and cognition who have detectable cerebrovascular disease (>0.5% WMH fraction of intracranial volume) on functional outcomes. The study is a prospective randomized, open-label trial with blinded end points, in patients ages ≥75 years with elevated 24-hour systolic blood pressure (BP) (145 mm Hg in the untreated state) who do not have unstable cardiovascular disease, heart failure, or stroke. The primary and key secondary outcomes in the trial are change from baseline in mobility and cognitive function and damage to brain white matter as demonstrated by accrual of WMH volume and changes in diffusion tensor imaging. Approximately 300 patients will be enrolled, and 200 randomized to 1 of 2 levels of ABP control (intensive to achieve a goal 24-hour systolic BP of ≤130 mm Hg or standard to achieve a goal 24-hour systolic BP of ≤145 mm Hg) for a total of 36 months using similar antihypertensive regimens. The analytical approach provides 85% power to show a clinically meaningful effect in differences in mobility accompanied by quantitative differences in WMH between treatment groups. The INFINITY trial is the first to guide antihypertensive therapy using ABP monitoring rather than clinic BP to reduce cerebrovascular disease.

Indexed as

AgedAged, 80 and overAntihypertensive AgentsBlood PressureBlood Pressure Monitoring, AmbulatoryCerebrovascular DisordersCognition DisordersDouble-Blind MethodFemaleHumansHypertensionLeukoencephalopathiesMagnetic Resonance ImagingMaleMobility LimitationProspective StudiesAntihypertensive Agents

Identifiers

PMID23453090
PMCPMC3587966
OpenAlexW2075082363

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.